Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of IV vs Oral Perampanel in Healthy Subjects
NCT03376997Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2017
- Primary completion
- Feb 2018
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of perampanel in epilepsy (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Concentration at 504 hours, Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration at 504 hours and 1 more. Started Nov 2017; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03376997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03376997.